Table 1 Characteristics of the study cohort and experimental measurements.
all volunteers | age groups [years] | ||||
|---|---|---|---|---|---|
<30 | 30 - 50 | >50 | |||
[n] | 181 | 51 | 70 | 60 | |
male/female | [n] | 105/76 | 28/23 | 42/28 | 35/25 |
age | [years] | 42 (18-88) | 25 (18-29) | 43 (30-50) | 58 (51-88) |
hemoglobin concentration | [g/L] | 139 (96-172) | 144 (122-172) | 138 (96-162) | 138 (104-159) |
platelet count | [×109/L] | 261 (150-509) | 275 (184-424) | 265 (193-509) | 252 (150-370) |
total leukocytes | [×109/L] | 5.9 (1.7-11.6) | 5.9 (3.6-11.6) | 6.1 (1.7-10.2) | 5.8 (3.3-9.5) |
total monocytes | [×106/L] | 450 (170-990) | 424 (170-810) | 462 (170-990) | 461 (190-880) |
CD14++CD16- monocytes | [%] | 7.05 (2.82-11.99) | 6.69 (2.82-11.49) | 7.14 (2.86-11.93) | 7.26 (3.44-11.99) |
CD14++CD16- monocytes | [×106/L] | 412.8 (155.1-903.0) | 394.3 (155.1-776.5) | 414.3 (165.7-902.9) | 420.3 (165.2-902.9) |
CD14+CD16+ monocytes | [%] | 0.54 (0.14-1.93) | 0.42 (0.15-1.51) | 0.59 (0.14-1.71) | 0.69 (0.27-1.93) |
CD14+CD16+ monocytes | [×106/L] | 33.7 (8.15-107.6) | 24.3 (8.15-107.6) | 35.7 (8.28-106.1) | 37.8 (14.8-106.3) |
serum MCP-1/CCL2 | [pg/mL] | 555 (61-1851) | 450 (109-880) | 573 (122-1851) | 654 (61-1563) |
serum MIP1α/CCL3 | [pg/mL] | 178 (14-10084) | 470 (14-10084) | 172 (14-10000) | 123 (14-10000) |
serum MIP1β/CCL4 | [pg/mL] | 32 (6-1107) | 27 (10-1107) | 33 (6-413) | 32 (11-200) |
serum fractalkine/CX3CL1 | [pg/mL] | 27.0 (0-80.5) | 22.4 (0-62.6) | 30.5 (0-68.7) | 27.0 (0-80.5) |